Journal of Endocrinological Investigation

, Volume 11, Issue 4, pp 231–237 | Cite as

The influence of diabetes mellitus on thyrotropin response to thyrotropin-releasing hormone in untreated acromegalic patients

  • C. Shigemasa
  • K. Abe
  • S. Taniguchi
  • Y. Mitani
  • Y. Ueta
  • T. Adachi
  • K. Urabe
  • T. Tanaka
  • A. Yoshida
  • T. Hori
  • H. Mashiba


Impairment of thyrotropin (TSH) response to thyrotropin-releasing hormone (TRH) has been documented in patients with uncontrolled diabetes mellitus (DM). In acromegalic patients, however, there have been no data regarding TSH secretion studied taking the existence of DM into consideration. Therefore, we investigated the TSH response to TRH [expressed as TSH increment (†TSH)] in 14 untreated acromegalic patients, who did not show the suprasellar extension of adenoma, divided into two groups on the basis of either presence or absence of uncontrolled DM, and in 28 normal subjects. The mean max †TSH was significantly reduced (p< 0.02) in acromegalic patients despite similar mean serum T4 and free T4 index (FT41) levels. Furthermore, the mean basal and max †TSH in 7 patients with DM (FBS, 120–300 mg/dl; HbA1, 8.8–15.2%) were significantly lower than those in 7 patients without DM (p<0.05 and p<0.02, respectively) despite similar the mean serum T3, T4, FT41, growth hormone (GH) and prolactin (PRL) levels and sellar volume. In 4 patients with DM the TSH response to TRH 6–8 weeks after insulin therapy, when their HbA1 levels were normal, increased compared to that before insulin therapy. The mean max †TSH after selective adenomectomy in 8 patients (3 in DM group and 5 in non-DM group), whose fasting basal GH fell to less than 5 ng/ml, was almost identical to that in normal subjects. In conclusion, the present study suggests that the abnormality in TSH secretion in acromegalic patients may be increased by the existence of uncontrolled DM.


Acromegaly diabetes mellitus basal thyrotropin level thyrotropin response thyrotropin-releasing hormone 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Irie M., Tsushima T. Increase of serum growth hormone concentration following thyrotropin-releasing hormone injection in patients with acromegaly or gigantism. J. Clin. Endocrinol. Metab. 35: 97, 1972.PubMedCrossRefGoogle Scholar
  2. 2.
    Hall R., Besser G.M., Ormston B.J., Cryer R.J., McKendrick M. The thyrotropin-releasing hormone test in disease of the pituistry and hypothalamus. Lancet 1: 759, 1972.PubMedCrossRefGoogle Scholar
  3. 3.
    Lamberg B-A., Pelkonen R., Aro A., Grahne B. Thyroid function in acromegaly before and after transphencidal hypophysectomy followed by cryoapplication. Acta Endocrinol. (Kbh.) 82: 254, 1976.Google Scholar
  4. 4.
    Carmina E., Rosato F., Pirronello S., Janni A. Hypothalamic-pituitary-thyroid axis in acromegaly. J. Endocrinol. Invest. 6: 263, 1983.PubMedCrossRefGoogle Scholar
  5. 5.
    Cobb W.E., Reichlin S., Jackson I.M.D. Growth hormone secretory status is a determination of the thyrotropin response to thyrotropin-releasing hormone in euthyroid patients with hypothalamic-pituitary disease. J. Clin. Endocrinol. Metab. 52: 324, 1981.PubMedCrossRefGoogle Scholar
  6. 6.
    Tsuchiya H., Onishi T., Mori S., Kohno H., Imanaka S., Saitoh Y., Mogami H., Uosumi T., Kumahara Y. Normalization of thyroid stimulating hormone levels in acromegalic patients after selective adenomectomy. Endocrinol. Jpn. 31: 687, 1984.PubMedCrossRefGoogle Scholar
  7. 7.
    Morley J.E., Kelein C., Kalk W.J., Joffe B.I., Saffer D., Distiller L.A., Seftel H.C. Pituitary responsiveness to thyrotropin releasing hormone in insulin-dependent diabetes mellitus. Horm. Metab. Res. 10: 231, 1978.PubMedCrossRefGoogle Scholar
  8. 8.
    Naeije R., Golstein J., Clumeck N., Meinhold H., Senzel K.W., Vanhaelst L. A low T3 syndrome in diabetic ketoacidosis. Clin. Endocrinol. (Oxf.) 8: 467, 1978.CrossRefGoogle Scholar
  9. 9.
    Macfarlane I.A., Sheppard M.C., Gilbey S., Black E.G., Wright A.D. Thyroid stimulating hormone secretion in type I (insulin-dependent) diabetic patients: influence of metabolic control. Diabetologia 23: 471, 1982 (Abstract).Google Scholar
  10. 10.
    Kabadi U.M. Impaired pituitary thyrotroph function in uncontrolled type II diabetes mellitus: normalization on recovery. J. Clin. Endocrinol. Metab. 59: 521, 1984.PubMedCrossRefGoogle Scholar
  11. 11.
    Scanlon M.F., Rodriguez-Arnao M.D., McGreger A.M., Weightman D., Lewis M., Cook D.B., Gomez-Pan A., Hall R. Altered dopaminergic regulation of thyrotropin release in patients with prolactinoma: comparison with other tests of hypothalamic-pituitary function. Clin. Endocrinol. (Oxf.) 14: 133, 1981.CrossRefGoogle Scholar
  12. 12.
    Seki K., Kato K. Increased thyroid stimulating hormone response to thyrotropin-releasing hormone in hyperprolactinemic women. J. Clin. Endocrinol. Metab. 61: 1138, 1985.PubMedCrossRefGoogle Scholar
  13. 13.
    Di Chiro G., Nelson K.B. The volume of the sella turcica. Am. J. Roentgenol. 87: 989, 1962.Google Scholar
  14. 14.
    Sternberg L.A., Hardy P.H., Cuculis J.J., Meyer H.G. The unlabelled antibody enzyme method of immunohis-tochemistry. J. Histochem. Cytochem. 18: 315, 1970.CrossRefGoogle Scholar
  15. 15.
    Faglia G., Paracchi A., Ferrari C., Beck-Peccoz P. Evaluation of results of transsphenoidal surgery in acromegaly by assessment of the growth hormone response to thyrotropin-releasing hormone. Clin. Endocrinol. (Oxf.) 8: 373, 1978.CrossRefGoogle Scholar
  16. 16.
    Chihara K., Minamitani N., Kaji H., Arimura A., Fujita T. Intraventricularly injected growth hormone stimulates somatostatin release into rat hypophysial portal blood. Endocrinology 109: 2279, 1981.PubMedCrossRefGoogle Scholar
  17. 17.
    Berelowitz M., Firestone S.C., Frohman L.A. Effect of growth hormone excess and deficiency on hypothalamic somatostatin content and release and on tissue somatostatin distribution. Endocrinology 109: 714, 1981.PubMedCrossRefGoogle Scholar
  18. 18.
    Weeke J., Hansen A.P, Lundaek K. Inhibition by somatostatin of basal levels of serum thyrotropin (TSH) in normal men. J. Clin. Endocrinol. Metab. 41: 168, 1975.PubMedCrossRefGoogle Scholar
  19. 19.
    Siler T.M., Yen S.S.C., Vale W., Guillemin R. Inhibition by somatostatin on the release of TSH induced in man by thyrotropin-releasing factor. J. Clin. Endocrinol. Metab. 38: 742, 1974.PubMedCrossRefGoogle Scholar
  20. 20.
    Wilber J.F, Benerji A., Prasad C., Mori M. Alterations in hypothalamic-pituitary-thyroid regulation produced by diabetes mellitus. Life Sci. 28: 1757, 1981.PubMedCrossRefGoogle Scholar
  21. 21.
    Itoh M., Hirooka Y., Nihei N. Response of plasma somatostatin-like immunoreactivity (SLI) to a 75 g oral glucose tolerance test in normal subjects and patients with impaired glucose tolerance. Acta Endocrinol. (Kbh.) 104: 468, 1983.Google Scholar
  22. 22.
    Orci L., Baetens D., Rufener C., Amherdt M., Ravazzola M., Studer P., Malaisse-Lagae F., Unger R. Hypertrophy and hyperplasia of somatostatin containing D-cells in diabetes. Proc. Natl. Acad. Sci. USA 73: 1338, 1976.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Wasada T., Funakoshi A. Endocrine dysfunction in diabetes mellitus: the release of somatostatin. J. Jpn. Diab. Soc. 28: 212, 1985 (Abstract, in Japanese).Google Scholar
  24. 24.
    Saito H., Yamasaki R., Hosoi E. Biochemical tests in blood and urine and immunological tests: somatostatin. Jpn. J. Clin. Med. 43 (an extra issue): 1029, 1985 (in Japanese).Google Scholar
  25. 25.
    Quigley M.E., Yen S.C.C. Evidence for increased dopaminergic inhibition of secretion of thyroid-stimulating hormone in hyperprolactinemic patients with pituitary microadenoma. Am. J. Obstet. Gynecol. 137: 653, 1980.PubMedGoogle Scholar
  26. 26.
    Hirvonen E., Rante T., Seppala M. Prolactin and thyrotropin to thyrotropin-releasing hormone in patients with secondary amenorrhea: the effect of bromocriptine. J. Clin. Endocrinol. Metab. 42: 1024, 1976.PubMedCrossRefGoogle Scholar
  27. 27.
    Healy D.L., Pepperell R.J., Stockdale J., Bremner W.J., Burger H.G. Pituitary autonomy in hyperprolactinemic secondary amenorrhea: results of hypothalamic-pituitary testing. J. Clin. Endocrinol. Metab. 44: 809, 1977.PubMedCrossRefGoogle Scholar
  28. 28.
    Pittman C.S., Suda A.K., Chambers J.B., Ray G.Y. Impaired 3, 5, 3′-triiodothyronine (T3) production in diabetic patients. Metabolism 28: 333, 1979.PubMedCrossRefGoogle Scholar
  29. 29.
    Fujii S., Akai T., Tanaka S., Nakatani K., Kinoshita M., Seki J., Wada M. Thyroid hormone abnormalities in patients with diabetes mellitus. J. Endocrinol. Invest. 4: 71, 1981.PubMedCrossRefGoogle Scholar
  30. 30.
    Bagchi N., Brown T.R., Shivers B., Lucas S., Mack R.E. Decreased thyroidal response to thyrotropin in diabetic mice. Endocrinology 109: 1428, 1981.PubMedCrossRefGoogle Scholar
  31. 31.
    Kakezono F., Yamashita S., Yokoyama N., Morita S., Kubo I., Ohtakara S., Morimoto I., Ikari N., Izumi M., Nagataki S. Stimulation of thyroid adenylate cyclase activity by sera from patients with non-thyroidal illness. Acta Endocrinol. (Kbh.) 113: 340, 1986.Google Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1988

Authors and Affiliations

  • C. Shigemasa
    • 1
  • K. Abe
    • 2
  • S. Taniguchi
    • 1
  • Y. Mitani
    • 1
  • Y. Ueta
    • 1
  • T. Adachi
    • 1
  • K. Urabe
    • 1
  • T. Tanaka
    • 1
  • A. Yoshida
    • 1
  • T. Hori
    • 3
  • H. Mashiba
    • 1
  1. 1.The First Department of Internal MedicineTottori University School of MedicineYonago 683Japan
  2. 2.Department of NursingTottori University College of Medical Care TechnologyYonago 683Japan
  3. 3.Division of Neurosurgery, Institute of Neurological SciencesTottori University School of MedicineJapan

Personalised recommendations